Activity-based costing evaluation of a [18F]-fludeoxyglucose positron emission tomography study

Krug, Bruno; Zanten, A. van; Pirson, Anne-Sophie; Crott, Ralph

doi:10.1016/j.healthpol.2009.04.002

Cited by 17 publications

(12 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another advantage is the short uptake time of approximately 30 min pared to those of SPECT and bone scanning, and the higher costs [3,23]. The cost effectiveness of fluoride PET/CT imaging in the diagnosis of orthopedic diseases should be analyzed in further studies [23,24]. …”

Section: Discussionmentioning

confidence: 99%

Therapeutic impact of [18F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain

et al. 2010

View full text Add to dashboard Cite

Purpose To evaluate the therapeutic impact of [18 F]fluoride positron-emission tomography/computed tomography ([ 18 F]fluoride PET/CT) imaging on patients with unclear foot pain. Methods Twenty-eight patients were prospectively included in this study. Therapeutic management was defined by two experienced dedicated foot surgeons before and after [18 F] fluoride PET/CT imaging. Twenty-six patients underwent cross-sectional imaging [CT, magnetic resonance (MR)] prior to PET/CT. A retrospective analysis of the magnetic resonance imaging (MRI) diagnoses was performed when a therapy change occurred after PET/CT imaging. Results In 13/28 (46%) patients therapeutic management was changed due to PET/CT results. Management changes occurred in patients with the following diagnoses: os trigonum syndrome; sinus tarsi syndrome; os tibiale externum syndrome; osteoarthritis of several joints; nonconsolidated fragments; calcaneo-navicular coalition; plantar fasciitis; insertional tendinopathy; suggestion of periostitis; neoarticulations between metatarsal bones. Os trigonum, os tibiale externum, subtalar osteoarthritis and plantar fasciitis were only seen to be active on PET/CT images but not on MR images. Conclusion [18 F]fluoride PET/CT has a substantial therapeutic impact on management in patients with unclear foot pain.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic impact of [18F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain

et al. 2010

View full text Add to dashboard Cite

show abstract

“…The organisational impact of introducing a new medical device may include effects on space and staff, possible resistance to its adoption and approval of the capital investment [33,[42][43][44]. Even if no direct reorganisation is required-for example, if the new device is replacing a similar one-cost savings may be achieved due to the improved efficacy of the new device [35].…”

Section: Measuring the Effect Of Organisational Changementioning

confidence: 99%

A Review of the Economic Tools for Assessing New Medical Devices

Craig

Carr

Hutton

et al. 2014

Appl Health Econ Health Policy

View full text Add to dashboard Cite

Whereas the economic evaluation of pharmaceuticals is an established practice within international health technology assessment (HTA) and is often produced with the support of comprehensive methodological guidance, the equivalent procedure for medical devices is less developed. Medical devices, including diagnostic products, are a rapidly growing market in healthcare, with over 10,000 medical technology patent applications filed in Europe in 2012-nearly double the number filed for pharmaceuticals. This increase in the market place, in combination with the limited, or constricting, budgets that healthcare decision makers face, has led to a greater level of examination with respect to the economic evaluation of medical devices. However, methodological questions that arise due to the unique characteristics of medical devices have yet to be addressed fully. This review of journal publications and HTA guidance identified these characteristics and the challenges they may subsequently pose from an economic evaluation perspective. These unique features of devices can be grouped into four categories: (1) data quality issues; (2) learning curve; (3) measuring long-term outcomes from diagnostic devices; and (4) wider impact from organisational change. We review the current evaluation toolbox available to researchers and explore potential future approaches to improve the economic evaluation of medical devices.

show abstract

“…We used a microcosting approach to calculate the true actual costs spent in performing a PET-CT study [38].…”

Section: Model Inputsmentioning

confidence: 99%

Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma

et al. 2010

Self Cite

View full text Add to dashboard Cite

Activity-based costing evaluation of a [18F]-fludeoxyglucose positron emission tomography study

Cited by 17 publications

References 28 publications

Therapeutic impact of [18F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain

Therapeutic impact of [18F]fluoride positron-emission tomography/computed tomography on patients with unclear foot pain

A Review of the Economic Tools for Assessing New Medical Devices

Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma

Contact Info

Product

Resources

About